MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

Core Viewpoint - MAIA Biotechnology, Inc. has announced a public offering of 20 million shares at a price of $1.50 per share, aiming to raise $30 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering consists of 20,000,000 shares priced at $1.50 each, with expected gross proceeds of $30 million before expenses [1]. - The underwriters have a 45-day option to purchase an additional 3,000,000 shares at the same price to cover over-allotments [1]. - The offering is structured as a common stock-only investment with no warrant coverage [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for conducting clinical trials, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on August 23, 2023 [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC [4]. Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [7].